Targeting CD79b in B-cell malignancies Book Section

  


Authors: Owens, C.; Salles, G.; O'Connor, O. A.; Ansell, S. M.; Gribben, J. G.
Editors: O'Connor, O. A.; Ansell, S. M.; Gribben, J. G.
Article/Chapter Title: Targeting CD79b in B-cell malignancies
Abstract: Polatuzumab vedotin is a CD79b directed antibody coupled with the synthetic microtubule agent MMAE (monomethyl auristatin E), having shown activity in various preclinical models. Polatuzumab vedotin has been successfully combined with an established immunochemotherapy regimen used for patients with diffuse large B-cell lymphoma, significantly improving the outcome of certain groups of patients. © 2024 John Wiley & Sons Ltd.
Keywords: polatuzumab vedotin; resistance mechanism; b cell malignancies; cd 79b; relapsed/refractory dlbcl
Book Title: Precision Cancer Therapies: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice
Volume: 2
ISBN: 9781119824541
Publisher: Wiley Blackwell  
Publication Place: Hoboken, NJ
Date Published: 2024-01-01
Start Page: 100
End Page: 107
Language: English
DOI: 10.1002/9781119824572.ch8
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85193896767&doi=10.1002%2f9781119824572.ch8&partnerID=40&md5=700eb049c06e3f625037ced44d01125e
Notes: Book chapter: 8 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Colette Ngozi Owens
    67 Owens
  2. Gilles Andre Salles
    272 Salles
Related MSK Work